Latest News

Palantir may hit $1B in quarterly revenue by late 2025, but with a forward P/E over 400, its stock remains priced for long-term hypergrowth

Alibaba has made a new move to expand its data center presence in the Asian region, signaling new potential upside to be had in the coming months.

The world's second-largest cryptocurrency is still a worthwhile investment.

Your savings account could be paying you pennies while your money loses value. See why it's time to switch to a high-yield savings account that actually pays.

Earning $20,000 in dividend income is an impressive accomplishment, but there's more to do to ensure he's ready for retirement.

The United States produces domestically just over half the refined copper it consumes each year.

Shares of EssilorLuxottica SA jumped on Wednesday following Meta Platforms’ reported minority investment in the company, with the tech giant further looking to increase its stake in the Ray-Ban maker to strengthen the long-term partnership.

Investors are watching for President Donald Trump’s trade announcements and the Fed minutes for signals on the dollar, inflation, rate cuts, and broader macro trends that may impact the price of Bitcoin.

Investors often regret fear-based decisions.

Chinese stocks are poised to achieve their best closing figures in three years, as investors speculate on potential measures to alleviate deflationary pressures and invigorate the economy.

Merck will acquire Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.

A significant trading signal occurred for MercadoLibre stock, as it demonstrated a power inflow at $2443.25, after which MELI rose nearly 1.4%.

Private equity firms bid up to $10 billion for a stake in Starbucks' China business, amid competition and declining market share.

While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%.

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong growth, profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy.

VERVE THERAPEUTICS (VERV) is a high-growth biotech stock meeting Minervini's Trend Template criteria, with strong revenue growth, bullish technicals, and upward earnings revisions.